<DOC>
	<DOCNO>NCT00691002</DOCNO>
	<brief_summary>There therapy suitable treatment psoriasis face skin fold . As area sensitive , irritation adverse reaction common elsewhere body . The purpose study compare efficacy safety daily treatment 8 week ointment contain calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g calcipotriol 25 mcg/g ointment vehicle , hydrocortisone 10 mg/g ointment vehicle ointment vehicle alone patient psoriasis vulgaris face intertriginous area ( = double-blind phase ) . Furthermore , safety efficacy evaluate 60 week treatment require calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g ointment psoriasis vulgaris face intertriginous area ( = open-label phase ) .</brief_summary>
	<brief_title>Efficacy Safety Calcipotriol Plus Hydrocortisone Ointment Psoriasis Vulgaris Face Skin Folds</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Clinical diagnosis psoriasis vulgaris involve face Clinical sign psoriasis vulgaris trunk and/or limb , early diagnose psoriasis vulgaris trunk and/or limbs An extent psoriatic involvement face least 10 cm2 ( sum facial lesion ) Treatment area ( face intertriginous area ) amenable topical treatment maximum 100 g ointment per week Disease severity grade mild , moderate , severe severe accord investigator 's global assessment disease severity face Systemic treatment therapy biologicals , potential effect psoriasis vulgaris ( e.g. , corticosteroid , vitamin D analogue , retinoids , immunosuppressant ) within 4week period prior randomisation Systemic use biological treatment , whether market , direct potential effect psoriasis vulgaris ( e.g. , alefacept , efalizumab , etanercept , infliximab , adalimumab ) within 3 month prior randomisation PUVA therapy Grenz ray therapy within 4week period prior randomisation UVB therapy within 2week period prior randomisation Topical treatment face intertriginous area within 2week period prior randomisation ( use emollient allow treatment area 2week period , doubleblind phase study ) Topical treatment potent WHO group IV corticosteroid within 2week period prior randomisation Initiation expect change concomitant medication may affect psoriasis vulgaris ( e.g. , beta blocker , antimalaria drug , lithium ACE inhibitor ) study Current diagnosis erythrodermic , exfoliative , guttate pustular psoriasis Patients follow condition present treatment area : viral ( e.g. , herpes varicella ) lesion skin , fungal bacterial skin infection , parasitic infection , skin manifestation relation syphilis tuberculosis , rosacea , perioral dermatitis , acne vulgaris , atrophic skin , stria atrophicae , fragility skin vein , ichthyosis , acne rosacea , ulcer wound Other inflammatory skin disease ( e.g. , seborrhoiec dermatitis , contact dermatitis cutaneous mycosis ) may confound evaluation psorisis vulgaris face intertriginous area Planned exposure sun , UVA UVB may affect psoriasis vulgaris study Known suspect severe renal insufficiency severe hepatic disorder Known suspected disorder calcium metabolism associate hypercalcaemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>